Table 2.
Results of the deterministic analysis base case
| Variables | GClb | RClb | Difference |
|---|---|---|---|
| Life years | 5.806 | 5.089 | 0.717 |
| In PFS | 2.825 | 1.711 | 1.114 |
| In PD | 2.980 | 3.378 | −0.397 |
| QALYs | 4.022 | 3.350 | 0.673 |
| In PFS | 2.248 | 1.339 | 0.909 |
| In PD | 1.774 | 2.011 | −0.236 |
| Costs | €35,142 | €18,426 | €16,716 |
| In PFS | €32,754 | €16,058 | €16,696 |
| In PD | €2,388 | €2,368 | €20 |
| Cost per LYG | €23,314 | – | – |
| Cost per QALY gained | €24,838 | – | – |
Abbreviations: GClb, obinutuzumab + chlorambucil; LYG, life years gained; PD, progression disease; PFS, progression-free survival; QALY, quality-adjusted life year; RClb, rituximab + chlorambucil.